The HSPA2 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population generated through targeted disruption of the HSPA2 gene in the HT29 human colon adenocarcinoma cell line. This polyclonal format encompasses a heterogeneous mix of edited cells, reflecting diverse CRISPR/Cas9-induced modifications and enabling robust loss-of-function analyses without clonal isolation. The model serves as a versatile platform for exploring HSPA2-dependent molecular mechanisms in a colorectal cancer context.
The HT29 cell line was established from a primary colorectal adenocarcinoma of a 44-year-old female patient and is widely recognized for its utility in studying intestinal epithelial cell differentiation, transport processes, and colorectal cancer biology. These epithelial cells retain the ability to differentiate and are extensively used to investigate oncogenic signaling, tumor progression, and therapeutic resistance.
HSPA2 encodes a molecular chaperone of the HSP70 family that plays a pivotal role in protein folding, stabilization, and cellular stress adaptation. Transcriptionally upregulated by heat shock factor 1 (HSF1) in response to heat shock, oxidative stress, and the inflammatory cytokine TNF-??, HSPA2 functions as a central hub in stress signaling. It physically interacts with co-chaperones including DNAJB1, STIP1 (HOP), and BAG family proteins, and collaborates with HSP90 to fold and protect client proteins. Critically, HSPA2 chaperones and stabilizes the oncogenic kinases AKT and ERK, thereby sustaining pro-survival cascades through the PI3K/AKT and MAPK pathways. By preserving AKT and ERK activity, HSPA2 promotes the expression of anti-apoptotic Bcl-2 proteins and suppresses caspase-mediated apoptosis, while also engaging NF-??B signaling to reinforce cell survival programs.
In colorectal cancer, overexpression of HSPA2 has been associated with chemoresistance and aggressive tumor behavior. By shielding AKT and ERK from degradation, HSPA2 amplifies proliferative and survival signals that counteract chemotherapy-induced apoptosis. The HT29 model, which maintains wild-type p53 and active oncogenic networks, provides a clinically relevant system to assess the consequences of HSPA2 loss. Disruption of HSPA2 is anticipated to diminish chaperoning of these kinases, sensitize cells to apoptotic stimuli, and attenuate NF-??B-driven transcription, potentially reversing drug-tolerant phenotypes.
This polyclonal knockout cell population supports a wide range of experimental applications. Researchers can employ western blotting, RT-qPCR, and immunofluorescence to verify HSPA2 ablation and monitor downstream molecules such as AKT, ERK, and Bcl-2. Functional assays??including MTT viability, Annexin V apoptosis, colony formation, and migration/invasion tests??enable quantitative assessment of cellular phenotypes following HSPA2 loss. Co-immunoprecipitation and drug sensitivity assays further allow investigation of HSPA2 interactomes and the impact on chemotherapeutic response. The model is particularly valuable for screening small-molecule inhibitors targeting HSPA2 or its co-chaperones. For additional information, please contact Ascent Research.
